Discovery and validation of a 10-gene predictive signature for response to adjuvant chemotherapy in stage II and III colon cancer.

Despite the relatively small sample size of the chemotherapy-benefit validation cohort (56 patients with 13 recurrent events), the 10-gene chemotherapy-benefit signature also achieved marginal significance (log rank p value = 0.0583), indicating a promising trend that distinguishes 5-FU-based ACT-beneficial and non-beneficial groups in terms of survival outcomes.

also in 3,086 other papers